RTW | Jotup

Transaction Update

Retrieved on:

Wednesday, February 7, 2024

RTW, Regulation D, Financial services, CREST, Calendar, Prejudice, International (Amtrak train), Person, Jefferies, Regulation, Second, Risk, Letter, Sale, Form, Security (finance)

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points:

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
Consideration Shares will be offered and sold outside of the United States to investors that are not U.S.
RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Retrieved on:

Thursday, February 1, 2024

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.

Key Points:

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.
Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners will serve as Chairman of Basking’s Board of Directors .
Basking will utilize the proceeds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.
Basking will initiate a Phase 2 proof-of-concept trial, the RAISE trial, in patients with acute ischemic stroke (AIS) in 2024.

Update on the Scheme and Publication of Notice of Second General Meeting

Retrieved on:

Tuesday, January 30, 2024

Jefferies, International (Amtrak train), Financial services, Person, Letter, Prejudice, Form, Risk, Regulation D, Sale, RTW, Second, Regulation, CREST, Calendar, Security (finance)

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points:

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.
If the Second General Meeting is adjourned, the Voting Record Time for the adjourned meeting will be 6.30 p.m. on the date two calendar days before the date set for the adjourned meeting.

Results of First General Meeting

Retrieved on:

Tuesday, January 30, 2024

Jefferies, International (Amtrak train), Financial services, Person, Letter, Prejudice, Risk, Regulation D, Sale, RTW, Regulation

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points:

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
This announcement is not an offer of securities for sale into the United States.
The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Update on the Scheme and Resignation of Directors

Retrieved on:

Tuesday, January 30, 2024

Jefferies, International (Amtrak train), Financial services, GBP, Person, Letter, Prejudice, Risk, Regulation D, Sale, RTW, Regulation

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points:

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
This announcement is not an offer of securities for sale into the United States.
The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023

Retrieved on:

Tuesday, January 9, 2024

Surgery, Medical Devices, Other Health, Health, Clinical Trials, Sale, RTW, Exercise, ESTA, Growth, Security (finance)

The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.

Key Points:

The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.
Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be in the range of $31.4 million to $31.8 million, in line with the guidance provided on November 7 in the third quarter earnings release.
Based on the expected range for fourth quarter preliminary unaudited revenue, Establishment Labs expects full-year 2023 revenue of $165.0 million to $165.4 million.
Establishment Labs expects to use net proceeds from the private placement for working capital and other general corporate purposes.

EQS-News: Immunic, Inc. Announces Private Placement of up to $240 Million

Retrieved on:

Friday, January 5, 2024

Janus, Sale, Public expenditure, Clinical trial, SVB Securities, Investment, RTW, Prospectus, Exchange, Exercise, Security (finance)

The first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions.

Key Points:

The first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions.
The third tranche is conditioned on the same volume weighted average share price levels and minimum trading volumes as the second tranche.
Leerink Partners is acting as the lead placement agent and Ladenburg Thalmann is acting as a placement agent in connection with the financing.
Immunic has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the securities issued in the private placement.

Publication of Circular and RTW Bio Prospectus

Retrieved on:

Friday, January 5, 2024

Regulation, Risk, Regulation D, Sale, Form, Letter, Jefferies, Financial services, CREST, Calendar, Person, RTW, Second, International (Amtrak train), Prejudice, Security (finance)

Investors in RTW Bio will therefore not receive the protections afforded by the 1940 Act to investors in a registered investment company.

Key Points:

Investors in RTW Bio will therefore not receive the protections afforded by the 1940 Act to investors in a registered investment company.
If RTW Bio is deemed to be an investment company and therefore is required to register under the 1940 Act, such requirement could prohibit RTW Bio from operating in its intended manner and could have a material adverse effect on RTW Bio.
RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.
RTW Bio further reserves the right to require the transfer or redemption of Consideration Shares held by any person for any reason, including circumstances that may prejudice the tax status of RTW Bio, may cause RTW Bio to be in violation of the Securities Act, the 1940 Act or any applicable state securities act or may cause RTW Bio to suffer any pecuniary, fiscal or administrative disadvantage which may be unlawful or detrimental to the interests or well-being of RTW Bio.

Update regarding timing of Proposed Scheme of Reconstruction

Retrieved on:

Monday, December 25, 2023

Regulation, Financial Conduct Authority, Risk, Jefferies, International (Amtrak train), Prejudice, Sale, Person, Regulation D, RTW, Letter, Security (finance), Financial adviser

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points:

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
persons” (as defined in Rule 902 under the Securities Act), except pursuant to an applicable exemption from registration.
The New RTW Bio Shares will be offered and sold for investment purposes only in the United States or to U.S.
New RTW Bio Shares will be offered and sold outside of the United States to investors that are not U.S.

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Retrieved on:

Tuesday, November 14, 2023

JDRF, Food, RTW, Entrepreneurship, Disease, ATG, Patient, Investment, FDA, SAB, ATW, Trial of the century, Partnership, Immunotherapy, Blaine Higgs, Pharmaceutical industry, Security (finance), T1D

The proceeds from the financing will be used to fund the development of the company’s lead research program, SAB-142, a potential disease modifying treatment for T1D.

Key Points:

The proceeds from the financing will be used to fund the development of the company’s lead research program, SAB-142, a potential disease modifying treatment for T1D.
Tranche B warrants remain outstanding, which if exercised, would result in a total of $110 million in proceeds in this financing.
Participating investors included Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and the JDRF T1D Fund.
SAB-142 directly targets multiple immune cells involved in destroying insulin-producing pancreatic beta cells to potentially preserve beta cell function.